Innoviva (NASDAQ:INVA) will release its earnings data after the market closes on Wednesday, February 7th. Analysts expect Innoviva to post earnings of $0.38 per share for the quarter.
Innoviva (NASDAQ:INVA) opened at $14.39 on Monday. The firm has a market cap of $1,550.00, a price-to-earnings ratio of 18.22 and a beta of 2.52. The company has a current ratio of 6.71, a quick ratio of 6.71 and a debt-to-equity ratio of -2.59. Innoviva has a 52-week low of $10.57 and a 52-week high of $16.11.
In other news, CFO Eric Desparbes sold 15,285 shares of the business’s stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $13.28, for a total transaction of $202,984.80. Following the transaction, the chief financial officer now owns 337,027 shares in the company, valued at approximately $4,475,718.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP George B. Abercrombie sold 5,215 shares of the business’s stock in a transaction dated Tuesday, November 21st. The stock was sold at an average price of $13.26, for a total transaction of $69,150.90. Following the transaction, the vice president now owns 263,866 shares in the company, valued at approximately $3,498,863.16. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 32,522 shares of company stock worth $429,985. Insiders own 1.60% of the company’s stock.
A number of research firms have weighed in on INVA. Zacks Investment Research lowered shares of Innoviva from a “hold” rating to a “sell” rating in a research report on Saturday. BidaskClub upgraded shares of Innoviva from a “hold” rating to a “buy” rating in a report on Thursday, December 21st. Deutsche Bank assumed coverage on shares of Innoviva in a report on Monday, November 20th. They set a “hold” rating and a $13.00 price objective on the stock. Robert W. Baird restated a “hold” rating and set a $13.00 price objective on shares of Innoviva in a report on Tuesday, October 24th. Finally, Cowen set a $16.00 price objective on shares of Innoviva and gave the stock a “buy” rating in a report on Monday, October 23rd. Two analysts have rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $13.50.
ILLEGAL ACTIVITY NOTICE: This report was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://transcriptdaily.com/2018/02/05/innoviva-inva-scheduled-to-post-quarterly-earnings-on-wednesday.html.
Innoviva Company Profile
Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).
Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.